{"id":"chemotherapy-folfirinox-6-cycles","safety":{"commonSideEffects":[{"rate":"75–90","effect":"Neutropenia"},{"rate":"60–75","effect":"Anemia"},{"rate":"40–50","effect":"Thrombocytopenia"},{"rate":"50–60","effect":"Diarrhea"},{"rate":"60–75","effect":"Nausea/vomiting"},{"rate":"40–50","effect":"Peripheral neuropathy"},{"rate":"60–70","effect":"Fatigue"},{"rate":"30–40","effect":"Mucositis"},{"rate":"10–20","effect":"Febrile neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFIRINOX combines four cytotoxic agents: 5-fluorouracil (5-FU) and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis, irinotecan inhibits topoisomerase I to prevent DNA unwinding, and oxaliplatin creates DNA cross-links. Together, these agents attack cancer cells through complementary pathways, maximizing cytotoxic effect while allowing for dose optimization.","oneSentence":"FOLFIRINOX is a combination chemotherapy regimen that damages cancer cell DNA through multiple mechanisms, preventing replication and inducing cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:32.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer"},{"name":"Locally advanced pancreatic cancer"},{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT04472910","phase":"NA","title":"GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-21","conditions":"Resectable Pancreatic Cancer","enrollment":84},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT05065801","phase":"PHASE2","title":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2022-01-11","conditions":"Metastatic Pancreatic Cancer","enrollment":162},{"nctId":"NCT06122480","phase":"NA","title":"Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-05-21","conditions":"Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease","enrollment":5},{"nctId":"NCT06384560","phase":"PHASE1, PHASE2","title":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2024-09-23","conditions":"Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":66},{"nctId":"NCT04749108","phase":"PHASE2, PHASE3","title":"Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-11-26","conditions":"Locally Advanced Malignant Neoplasm, Rectal Carcinoma","enrollment":1075},{"nctId":"NCT03875781","phase":"PHASE3","title":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-05","conditions":"Rectal Cancer, Advanced Cancer","enrollment":540},{"nctId":"NCT03991962","phase":"PHASE2","title":"Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2019-09-24","conditions":"Pancreatic Cancer","enrollment":28},{"nctId":"NCT06402864","phase":"PHASE3","title":"Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-03-26","conditions":"Adult With Intermediate Low or Mid Rectal Adenocarcinoma","enrollment":212},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT05417386","phase":"PHASE1","title":"FOLFIRINOX + NIS793 in Pancreatic Cancer","status":"TERMINATED","sponsor":"Colin D. Weekes, M.D., PhD","startDate":"2022-08-09","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":4},{"nctId":"NCT04481204","phase":"PHASE2","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-18","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma","enrollment":105},{"nctId":"NCT03563248","phase":"PHASE2","title":"Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-08-10","conditions":"Pancreatic Cancer","enrollment":168},{"nctId":"NCT04325425","phase":"PHASE2","title":"Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-09-01","conditions":"Neuroendocrine Carcinoma","enrollment":218},{"nctId":"NCT07096362","phase":"PHASE2","title":"Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-09-09","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":50},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT06249321","phase":"PHASE2","title":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Pancreatic Cancer, Radiotherapy","enrollment":30},{"nctId":"NCT06149689","phase":"PHASE2","title":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-01-10","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT05132504","phase":"PHASE2","title":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-08-31","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT06813976","phase":"PHASE3","title":"PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2025-07-02","conditions":"Ampullary Adenocarcinoma","enrollment":294},{"nctId":"NCT06057831","phase":"PHASE2","title":"PET/MRI in Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2026-05","conditions":"Rectal Cancer","enrollment":40},{"nctId":"NCT01804790","phase":"PHASE3","title":"Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-01","conditions":"Cancer of the Rectum","enrollment":461},{"nctId":"NCT01821612","phase":"EARLY_PHASE1","title":"Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2013-05-29","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":23},{"nctId":"NCT06714604","phase":"PHASE3","title":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","status":"RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2023-10-18","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer","enrollment":432},{"nctId":"NCT05534087","phase":"PHASE3","title":"Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2022-12-15","conditions":"Colon Cancer","enrollment":236},{"nctId":"NCT06681038","phase":"PHASE2","title":"Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)","status":"NOT_YET_RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2025-02","conditions":"Peritoneal Metastases from Colorectal Cancer","enrollment":114},{"nctId":"NCT03879109","phase":"PHASE3","title":"Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2019-07-08","conditions":"Rectal Cancer","enrollment":58},{"nctId":"NCT01595321","phase":"PHASE2","title":"Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-10-29","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT06378580","phase":"","title":"The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Luo Cong","startDate":"2022-07-01","conditions":"Pancreatic Cancer","enrollment":72},{"nctId":"NCT01827553","phase":"PHASE3","title":"Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2013-04-04","conditions":"Pancreatic Cancer","enrollment":830},{"nctId":"NCT05868317","phase":"PHASE2","title":"Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer","status":"UNKNOWN","sponsor":"Salah Azaïz Cancer Institute","startDate":"2020-11-01","conditions":"Rectal Cancer, Locally Advanced","enrollment":70},{"nctId":"NCT04617821","phase":"PHASE3","title":"AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-09-01","conditions":"Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma","enrollment":300},{"nctId":"NCT05066802","phase":"PHASE2","title":"A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-05-11","conditions":"Resectable Pancreatic Adenocarcinoma","enrollment":27},{"nctId":"NCT03536182","phase":"PHASE3","title":"Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-05-29","conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT04393584","phase":"PHASE2, PHASE3","title":"FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2019-01-29","conditions":"Stomach Neoplasms, Gastrointestinal Neoplasms, Docetaxel","enrollment":538},{"nctId":"NCT02172976","phase":"PHASE2, PHASE3","title":"Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2014-11","conditions":"Resectable Prancreas Carcinoma","enrollment":40},{"nctId":"NCT01560949","phase":"PHASE2","title":"Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-14","conditions":"Pancreatic Cancer","enrollment":34},{"nctId":"NCT04443543","phase":"PHASE2","title":"An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2020-06-22","conditions":"Rectal Cancer","enrollment":222},{"nctId":"NCT01836432","phase":"PHASE3","title":"Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2013-05","conditions":"Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm","enrollment":302},{"nctId":"NCT02749136","phase":"PHASE2","title":"Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2016-05","conditions":"Pancreatic Adenocarcinoma","enrollment":44},{"nctId":"NCT04130399","phase":"PHASE2","title":"Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Indiana University","startDate":"2019-07-01","conditions":"Pancreatic Cancer, Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT02548169","phase":"PHASE1","title":"Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Baylor Research Institute","startDate":"2015-08","conditions":"Pancreatic Cancer","enrollment":7},{"nctId":"NCT02592395","phase":"PHASE1","title":"Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2015-10","conditions":"Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT01333709","phase":"PHASE2","title":"Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2011-05","conditions":"Locally Advanced Malignant Neoplasm, Rectal Carcinoma","enrollment":150},{"nctId":"NCT01413022","phase":"PHASE1","title":"FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2012-04","conditions":"Pancreatic Neoplasms","enrollment":44},{"nctId":"NCT01488552","phase":"PHASE1, PHASE2","title":"Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Research Team","startDate":"2011-11","conditions":"Stage IV Pancreatic Cancer","enrollment":60},{"nctId":"NCT01446458","phase":"PHASE1","title":"Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-11","conditions":"Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic","enrollment":13},{"nctId":"NCT01760694","phase":"NA","title":"Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"Southwestern Regional Medical Center","startDate":"2013-01","conditions":"Pancreatic Cancer","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Chemotherapy FOLFIRINOX, 6 cycles","genericName":"Chemotherapy FOLFIRINOX, 6 cycles","companyName":"University Hospital, Bordeaux","companyId":"university-hospital-bordeaux","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFIRINOX is a combination chemotherapy regimen that damages cancer cell DNA through multiple mechanisms, preventing replication and inducing cell death. Used for Metastatic pancreatic cancer, Locally advanced pancreatic cancer, Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}